Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT Study

Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.

Karuna Therapeutics, Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer’s Disease.’ The study aims to assess the safety and effectiveness of KarXT in treating psychosis in adults with Alzheimer’s Disease, a significant concern due to the growing prevalence of Alzheimer’s globally.

The study tests the drug KarXT against a placebo. KarXT is an experimental drug designed to alleviate psychosis symptoms in Alzheimer’s patients, potentially offering a new treatment avenue for this challenging condition.

This interventional study is randomized and employs a parallel assignment model. It is quadruple-masked, meaning that the participant, care provider, investigator, and outcomes assessor are all unaware of the group assignments. The primary purpose of the study is treatment-focused.

The study began on September 26, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 14, 2025, indicating ongoing recruitment efforts.

The study’s progress could significantly impact Karuna Therapeutics’ stock performance, as successful results may enhance investor confidence and market position. In the competitive landscape of Alzheimer’s treatments, advancements in psychosis management could differentiate Karuna from its peers.

The study is currently recruiting, with further details available on the ClinicalTrials portal.